Takehiro Takahashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takehiro Takahashi has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Yoshihide Asano
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
18 shared publications Yoshihide Asano
10 shared publicationsYuichiro Segawa
8 shared publicationsTakuya Takahashi
7 shared publicationsToshiki Okazaki
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
7 shared publications- Toshiya Takahashi
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
7 shared publications
Latest Publications
- 1 October 2026
- Published by JLE in European Journal Of Dermatology
- Vol. 36 (5) , 452-454
A case of lesions resembling localized scleroderma in systemic sclerosis successfully treated with tocilizumab
- 1 October 2026
- Published by JLE in European Journal Of Dermatology
- Vol. 36 (5) , 452-454
A case of lesions resembling localized scleroderma in systemic sclerosis successfully treated with tocilizumab
- Open Access
- 1 October 2026
- Published by Elsevier in JAAD Case Reports
Pansclerotic morphea successfully treated with tocilizumab
- 1 October 2026
- Published by Elsevier in JAAD Case Reports
Open AccessPansclerotic morphea successfully treated with tocilizumab
- Open Access
- 21 September 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (4)
Sotatercept-related peripheral microvascular alterations in systemic sclerosis–associated pulmonary arterial hypertension: insights from nailfold capillaroscopy
- 21 September 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (4)
Open AccessSotatercept-related peripheral microvascular alterations in systemic sclerosis–associated pulmonary arterial hypertension: insights from nailfold capillaroscopy
- 15 July 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (9) , 1365-1370
IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients
Localized scleroderma (LSc) is an autoimmune fibrosing disorder characterized by inflammation and sclerosis of the skin and underlying soft tissues. IL‐17 signaling has been implicated in active inflammatory lesions, but treatment options for severe or refractory LSc remain limited. Here, we present nine patients with LSc treated with IL‐17A or IL‐17 receptor A inhibitors at our institution (ixekizumab, secukinumab, or brodalumab). These biologics were administered to patients refractory to conventional therapies or anticipated to have treatment‐resistant disease, following institutional approval for unapproved drug use. Five patients improved, two stabilized, and two progressed. One patient developed pustulotic arthro‐osteitis during brodalumab treatment, possibly representing a paradoxical reaction; no other major adverse events were observed. Although these uncontrolled retrospective data do not establish efficacy, they suggest that IL‐17 pathway inhibition merits further study in selected patients with refractory LSc.
- 15 July 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (9) , 1365-1370
IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients
Localized scleroderma (LSc) is an autoimmune fibrosing disorder characterized by inflammation and sclerosis of the skin and underlying soft tissues. IL‐17 signaling has been implicated in active inflammatory lesions, but treatment options for severe or refractory LSc remain limited. Here, we present nine patients with LSc treated with IL‐17A or IL‐17 receptor A inhibitors at our institution (ixekizumab, secukinumab, or brodalumab). These biologics were administered to patients refractory to conventional therapies or anticipated to have treatment‐resistant disease, following institutional approval for unapproved drug use. Five patients improved, two stabilized, and two progressed. One patient developed pustulotic arthro‐osteitis during brodalumab treatment, possibly representing a paradoxical reaction; no other major adverse events were observed. Although these uncontrolled retrospective data do not establish efficacy, they suggest that IL‐17 pathway inhibition merits further study in selected patients with refractory LSc.
- 24 March 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (5) , 409-421
Clinical positioning and future prospects of JAK inhibitors in alopecia areata
Alopecia areata (AA) is a chronic autoimmune disease characterized by non-scarring hair loss driven by cytotoxic attack against anagen hair follicles. Janus kinase (JAK) inhibitors disrupt the pathogenic signaling and have revolutionized treatment landscape for severe AA. Nevertheless, clinical unmet needs remain for the primary non-responders, relapse during treatment, and lack of reliable biomarkers to guide treatment discontinuation. This review summarizes evidence from pivotal clinical trials and real-world studies of JAK inhibitors in AA, focusing on treatment efficacy, achievement of a Severity of Alopecia Tool (SALT) score of ≤20, and long-term outcomes beyond 52 weeks. Post-hoc analyses addressing relapse after withdrawal, and dose reduction are also discussed. Furthermore, we overview real-world data highlighting clinical factors associated with treatment responses, including disease duration, baseline severity, and sex. A literature search was conducted primarily in PubMed for articles published up to November 2025, with additional website searches for company announcements and clinical trial related updates when relevant. JAK inhibitors have fundamentally redefined the therapeutic framework for severe AA and serve as the functional probes that clarify disease biology underlying AA. Emerging evidence suggests that early intervention and standardized monitoring based on clinical information should guide treatment design. Future challenges include systematizing strategies for continuation, dose reduction, temporary interruption, and reinitiation based on patient background, as well as developing more effective combination therapies.
- 24 March 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (5) , 409-421
Clinical positioning and future prospects of JAK inhibitors in alopecia areata
Alopecia areata (AA) is a chronic autoimmune disease characterized by non-scarring hair loss driven by cytotoxic attack against anagen hair follicles. Janus kinase (JAK) inhibitors disrupt the pathogenic signaling and have revolutionized treatment landscape for severe AA. Nevertheless, clinical unmet needs remain for the primary non-responders, relapse during treatment, and lack of reliable biomarkers to guide treatment discontinuation. This review summarizes evidence from pivotal clinical trials and real-world studies of JAK inhibitors in AA, focusing on treatment efficacy, achievement of a Severity of Alopecia Tool (SALT) score of ≤20, and long-term outcomes beyond 52 weeks. Post-hoc analyses addressing relapse after withdrawal, and dose reduction are also discussed. Furthermore, we overview real-world data highlighting clinical factors associated with treatment responses, including disease duration, baseline severity, and sex. A literature search was conducted primarily in PubMed for articles published up to November 2025, with additional website searches for company announcements and clinical trial related updates when relevant. JAK inhibitors have fundamentally redefined the therapeutic framework for severe AA and serve as the functional probes that clarify disease biology underlying AA. Emerging evidence suggests that early intervention and standardized monitoring based on clinical information should guide treatment design. Future challenges include systematizing strategies for continuation, dose reduction, temporary interruption, and reinitiation based on patient background, as well as developing more effective combination therapies.
- Open Access
- 18 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 691-695
Circumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes
Localized scleroderma (LSc) is an autoimmune condition characterized by localized cutaneous sclerosis, sometimes extending into deeper tissues. Phototherapy, including excimer laser therapy (ELT), is considered an effective and minimally invasive treatment option for patients without extracutaneous involvement. However, little is known about the histopathological and molecular alterations that occur during treatment. Here, we report a case of circumscribed morphea successfully treated with ELT, accompanied by detailed longitudinal histological analysis. A 78‐year‐old woman presented with gradually progressive indurated plaques on both sides of the abdomen. Histopathological examination of the lesional skin revealed dense collagen deposition and perivascular infiltration of lymphocytes, monocytes, and mast cells, confirming the diagnosis of circumscribed morphea. Topical glucocorticoid therapy yielded insufficient improvement, prompting the addition of 308‐nm ELT. The patient underwent 12 ELT sessions, administered every two to four weeks with incremental dosing from 100 mJ/cm 2 to 240 mJ/cm 2 , reaching a cumulative dose of 2100 mJ/cm 2 . This regimen resulted in marked clinical improvement within one year. Post‐treatment biopsies demonstrated near‐complete resolution of dermal sclerosis, with substantial reductions in inflammatory cell infiltration. Toluidine blue staining and immunohistochemistry further revealed dynamic cellular changes: mast cells and CD3 + T cells were significantly decreased; CD34 expression, absent in lesional dermal mesenchymal cells before treatment, was restored; and α‐smooth muscle actin‐positive myofibroblasts, abundant at baseline, were markedly reduced following ELT. These findings indicate that ELT not only ameliorates clinical sclerosis but also reverses immune and mesenchymal cell alterations associated with fibrosis. This case highlights the therapeutic potential of ELT in circumscribed morphea and suggests a plausible mechanism by which ELT modulates immune–mesenchymal interactions to attenuate fibrosis in LSc.
- 18 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 691-695
Open AccessCircumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes
Localized scleroderma (LSc) is an autoimmune condition characterized by localized cutaneous sclerosis, sometimes extending into deeper tissues. Phototherapy, including excimer laser therapy (ELT), is considered an effective and minimally invasive treatment option for patients without extracutaneous involvement. However, little is known about the histopathological and molecular alterations that occur during treatment. Here, we report a case of circumscribed morphea successfully treated with ELT, accompanied by detailed longitudinal histological analysis. A 78‐year‐old woman presented with gradually progressive indurated plaques on both sides of the abdomen. Histopathological examination of the lesional skin revealed dense collagen deposition and perivascular infiltration of lymphocytes, monocytes, and mast cells, confirming the diagnosis of circumscribed morphea. Topical glucocorticoid therapy yielded insufficient improvement, prompting the addition of 308‐nm ELT. The patient underwent 12 ELT sessions, administered every two to four weeks with incremental dosing from 100 mJ/cm 2 to 240 mJ/cm 2 , reaching a cumulative dose of 2100 mJ/cm 2 . This regimen resulted in marked clinical improvement within one year. Post‐treatment biopsies demonstrated near‐complete resolution of dermal sclerosis, with substantial reductions in inflammatory cell infiltration. Toluidine blue staining and immunohistochemistry further revealed dynamic cellular changes: mast cells and CD3 + T cells were significantly decreased; CD34 expression, absent in lesional dermal mesenchymal cells before treatment, was restored; and α‐smooth muscle actin‐positive myofibroblasts, abundant at baseline, were markedly reduced following ELT. These findings indicate that ELT not only ameliorates clinical sclerosis but also reverses immune and mesenchymal cell alterations associated with fibrosis. This case highlights the therapeutic potential of ELT in circumscribed morphea and suggests a plausible mechanism by which ELT modulates immune–mesenchymal interactions to attenuate fibrosis in LSc.
- 12 February 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4)
Adalimumab‐Induced Folliculitis‐Like Lichenoid Sarcoidosis
- 12 February 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4)
Adalimumab‐Induced Folliculitis‐Like Lichenoid Sarcoidosis
- Open Access
- 9 February 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (2) , e70220
Analysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment
Systemic sclerosis (SSc) is a systemic autoimmune disease characterised by vasculopathy and fibrosis of the skin and internal organs. In SSc, normal angiogenic processes are impaired due to abnormalities in vascular endothelial cells and pericytes. Nailfold videocapillaroscopy (NVC) is useful for evaluating microvascular injury in SSc. Tocilizumab (TCZ), an anti‐IL‐6 receptor antibody, has demonstrated efficacy in SSc‐associated interstitial lung disease (SSc‐ILD); however, its effects on vascular abnormalities in SSc remain poorly understood. We evaluated longitudinal changes in NVC findings in 13 SSc patients treated with monthly intravenous TCZ. Capillary density significantly increased at 6 months compared with baseline. This increase was positively and strongly correlated with improvements in pulmonary function test results. To further explore the correlation between NVC findings and angiogenic mediators, we quantified serum levels of seven pivotal angiogenic factors before and 6 months after TCZ initiation using a multiplex immunoassay. Among the angiogenic factors, serum levels of vascular endothelial growth factor (VEGF)‐A, platelet endothelial cell adhesion molecule (PECAM)‐1 and hepatocyte growth factor (HGF) were significantly intercorrelated and significantly decreased after 6 months of treatment. Notably, serum HGF levels showed the strongest correlation with capillary density and were also significantly correlated with modified Rodnan skin score. Furthermore, the decrease in serum VEGF‐A levels was robustly associated with improvements in pulmonary function test results. Our results collectively suggest that TCZ treatment is associated with changes in systemic vascular abnormalities and angiogenic factor profiles in SSc, which are critically involved in the pathophysiology of SSc‐associated interstitial lung disease.
- 9 February 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (2) , e70220
Open AccessAnalysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment
Systemic sclerosis (SSc) is a systemic autoimmune disease characterised by vasculopathy and fibrosis of the skin and internal organs. In SSc, normal angiogenic processes are impaired due to abnormalities in vascular endothelial cells and pericytes. Nailfold videocapillaroscopy (NVC) is useful for evaluating microvascular injury in SSc. Tocilizumab (TCZ), an anti‐IL‐6 receptor antibody, has demonstrated efficacy in SSc‐associated interstitial lung disease (SSc‐ILD); however, its effects on vascular abnormalities in SSc remain poorly understood. We evaluated longitudinal changes in NVC findings in 13 SSc patients treated with monthly intravenous TCZ. Capillary density significantly increased at 6 months compared with baseline. This increase was positively and strongly correlated with improvements in pulmonary function test results. To further explore the correlation between NVC findings and angiogenic mediators, we quantified serum levels of seven pivotal angiogenic factors before and 6 months after TCZ initiation using a multiplex immunoassay. Among the angiogenic factors, serum levels of vascular endothelial growth factor (VEGF)‐A, platelet endothelial cell adhesion molecule (PECAM)‐1 and hepatocyte growth factor (HGF) were significantly intercorrelated and significantly decreased after 6 months of treatment. Notably, serum HGF levels showed the strongest correlation with capillary density and were also significantly correlated with modified Rodnan skin score. Furthermore, the decrease in serum VEGF‐A levels was robustly associated with improvements in pulmonary function test results. Our results collectively suggest that TCZ treatment is associated with changes in systemic vascular abnormalities and angiogenic factor profiles in SSc, which are critically involved in the pathophysiology of SSc‐associated interstitial lung disease.
- 25 December 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 470-477
Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Alopecia areata (AA) is a chronic autoimmune disorder characterized by refractory non‐scarring hair loss. Although baricitinib revolutionized AA management, some severe cases remain refractory. Ritlecitinib, an oral selective dual JAK3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, is a recently approved therapeutic agent for the treatment of severe AA. Although clinical trials have established the benefit of ritlecitinib, real‐world data on its outcome and safety, particularly in patients previously exposed to baricitinib, have been still limited. Accordingly, we conducted a single‐center, retrospective study of 22 severe AA patients treated with ritlecitinib 50 mg daily for 24 weeks at Tohoku University Hospital, Japan. Nine patients (41%) were JAK inhibitor (JAKi)‐naïve, and 13 (59%) had previously received baricitinib for a median of 19 months. JAKi‐naïve patients were significantly younger (median 14 vs. 38 years; p = 0.0143) and had shorter current AA episodes (median 20 vs. 68 months; p = 0.0138), compared with the JAKi‐experienced group. Baseline SALT score in each group showed similar distribution. At Week 24, all JAKi‐naïve patients achieved SALT 50 (a decrease of at least 50% from baseline in the SALT score); 7/9 (78%) attained SALT ≤ 20 and SALT 75 (a decrease of at least 75% from baseline in the SALT score). In contrast, among JAKi‐experienced patients, only 3/13 (23%) achieved SALT 50 , and 1/13 (8%) reached SALT 75 , whereas a reduction in SALT score from baseline was observed in 7 of 13 (54%). Importantly, no patients in both groups experienced SALT worsening or treatment‐related adverse events. Our findings highlighted that ritlecitinib is highly effective especially in adolescent JAKi‐naïve AA, and although the clinical effect may be limited in JAKi‐experienced patients, switching from baricitinib to ritlecitinib remains one of the viable options due to its low risk of disease exacerbation.
- 25 December 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 470-477
Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Alopecia areata (AA) is a chronic autoimmune disorder characterized by refractory non‐scarring hair loss. Although baricitinib revolutionized AA management, some severe cases remain refractory. Ritlecitinib, an oral selective dual JAK3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, is a recently approved therapeutic agent for the treatment of severe AA. Although clinical trials have established the benefit of ritlecitinib, real‐world data on its outcome and safety, particularly in patients previously exposed to baricitinib, have been still limited. Accordingly, we conducted a single‐center, retrospective study of 22 severe AA patients treated with ritlecitinib 50 mg daily for 24 weeks at Tohoku University Hospital, Japan. Nine patients (41%) were JAK inhibitor (JAKi)‐naïve, and 13 (59%) had previously received baricitinib for a median of 19 months. JAKi‐naïve patients were significantly younger (median 14 vs. 38 years; p = 0.0143) and had shorter current AA episodes (median 20 vs. 68 months; p = 0.0138), compared with the JAKi‐experienced group. Baseline SALT score in each group showed similar distribution. At Week 24, all JAKi‐naïve patients achieved SALT 50 (a decrease of at least 50% from baseline in the SALT score); 7/9 (78%) attained SALT ≤ 20 and SALT 75 (a decrease of at least 75% from baseline in the SALT score). In contrast, among JAKi‐experienced patients, only 3/13 (23%) achieved SALT 50 , and 1/13 (8%) reached SALT 75 , whereas a reduction in SALT score from baseline was observed in 7 of 13 (54%). Importantly, no patients in both groups experienced SALT worsening or treatment‐related adverse events. Our findings highlighted that ritlecitinib is highly effective especially in adolescent JAKi‐naïve AA, and although the clinical effect may be limited in JAKi‐experienced patients, switching from baricitinib to ritlecitinib remains one of the viable options due to its low risk of disease exacerbation.
- Open Access
Recent Advances in Localized Scleroderma
Localized scleroderma (LSc), or morphea, is an autoimmune connective tissue disease causing inflammation and fibrosis of the skin and underlying tissues. While distinct from systemic sclerosis, its clinical presentation is highly diverse. This review summarizes recent advances in the understanding and management of LSc. Pathophysiological insights have evolved significantly; the somatic mosaicism hypothesis is now supported by the observation of all six of Happle’s classic lesion patterns in LSc. Furthermore, recent single-cell RNA sequencing has elucidated key cellular mechanisms, revealing an IFN-γ-driven pro-fibrotic crosstalk between T cells, dendritic cells, and specific inflammatory fibroblast subpopulations. The discovery of a rare monogenic form of LSc caused by a STAT4 gain-of-function mutation provides a powerful human model, solidifying the critical role of the JAK-STAT pathway. Clinically, LSc is classified into subtypes such as circumscribed, linear, and generalized morphea. Extracutaneous manifestations are common, particularly in juvenile LSc, and are associated with higher disease activity and reduced quality of life, necessitating a multidisciplinary approach. Management is becoming standardized, with methotrexate as the first-line systemic therapy for severe disease. For refractory cases, targeted treatments including abatacept, tocilizumab, and JAK inhibitors are emerging as promising options. In addition, reconstructive therapies like autologous fat grafting are crucial for managing atrophic sequelae. These recent advances are paving the way for more effective, targeted therapies to improve outcomes for patients with this complex disease.
Open AccessRecent Advances in Localized Scleroderma
Localized scleroderma (LSc), or morphea, is an autoimmune connective tissue disease causing inflammation and fibrosis of the skin and underlying tissues. While distinct from systemic sclerosis, its clinical presentation is highly diverse. This review summarizes recent advances in the understanding and management of LSc. Pathophysiological insights have evolved significantly; the somatic mosaicism hypothesis is now supported by the observation of all six of Happle’s classic lesion patterns in LSc. Furthermore, recent single-cell RNA sequencing has elucidated key cellular mechanisms, revealing an IFN-γ-driven pro-fibrotic crosstalk between T cells, dendritic cells, and specific inflammatory fibroblast subpopulations. The discovery of a rare monogenic form of LSc caused by a STAT4 gain-of-function mutation provides a powerful human model, solidifying the critical role of the JAK-STAT pathway. Clinically, LSc is classified into subtypes such as circumscribed, linear, and generalized morphea. Extracutaneous manifestations are common, particularly in juvenile LSc, and are associated with higher disease activity and reduced quality of life, necessitating a multidisciplinary approach. Management is becoming standardized, with methotrexate as the first-line systemic therapy for severe disease. For refractory cases, targeted treatments including abatacept, tocilizumab, and JAK inhibitors are emerging as promising options. In addition, reconstructive therapies like autologous fat grafting are crucial for managing atrophic sequelae. These recent advances are paving the way for more effective, targeted therapies to improve outcomes for patients with this complex disease.